Bifogade filer
ScandiDos’ directed share issue completed
Kurs
+8,76%
Likviditet
0,02 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-06-18 | 08:00 | Bokslutskommuniké 2025 |
| 2025-03-12 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2024-12-17 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2024-10-24 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2024-10-23 | - | Årsstämma |
| 2024-09-18 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-18 | - | Bokslutskommuniké 2024 |
| 2024-03-13 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-12 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-18 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2023-10-17 | - | Årsstämma |
| 2023-09-13 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-15 | - | Bokslutskommuniké 2023 |
| 2023-03-08 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-07 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-18 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2022-10-17 | - | Årsstämma |
| 2022-09-13 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-28 | - | Bokslutskommuniké 2022 |
| 2022-03-11 | - | Kvartalsrapport 2022-Q3 |
| 2021-12-14 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-21 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2021-10-20 | - | Årsstämma |
| 2021-09-23 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-29 | - | Bokslutskommuniké 2021 |
| 2021-03-10 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-16 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-07 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2020-10-06 | - | Årsstämma |
| 2020-09-25 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-26 | - | Bokslutskommuniké 2020 |
| 2020-03-10 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-18 | - | Kvartalsrapport 2020-Q2 |
| 2019-10-09 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2019-10-08 | - | Årsstämma |
| 2019-09-12 | - | Kvartalsrapport 2020-Q1 |
| 2019-06-28 | - | Bokslutskommuniké 2019 |
| 2018-12-14 | - | Kvartalsrapport 2019-Q2 |
| 2018-10-03 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2018-10-02 | - | Årsstämma |
| 2018-06-28 | - | Bokslutskommuniké 2018 |
| 2018-03-22 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-15 | - | Kvartalsrapport 2018-Q2 |
| 2017-10-03 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2017-10-02 | - | Årsstämma |
| 2017-09-29 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-28 | - | Bokslutskommuniké 2017 |
| 2017-03-22 | - | Kvartalsrapport 2017-Q3 |
| 2016-12-15 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-21 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2016-09-20 | - | Årsstämma |
| 2016-09-20 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-30 | - | Bokslutskommuniké 2016 |
| 2016-03-15 | - | Kvartalsrapport 2016-Q3 |
| 2015-12-11 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-24 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2015-09-23 | - | Årsstämma |
| 2015-09-23 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-23 | - | Bokslutskommuniké 2015 |
| 2015-03-26 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-19 | - | Kvartalsrapport 2015-Q2 |
| 2014-10-14 | - | Årsstämma |
| 2014-09-24 | - | X-dag ordinarie utdelning SDOS 0.00 SEK |
| 2014-09-23 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-13 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
ScandiDos AB (publ) ("ScandiDos") announced earlier this week that ScandiDos' Board of Directors has resolved on a directed share issue to IBA Dosimetry GmbH (a wholly owned subsidiary of IBA S.A.). The issue consisted of 4,150,000 shares at a subscription price of SEK 3 per share (the "Directed Issue"), which entailed a total subscription proceeds of SEK 12,45 million before transaction costs. IBA Dosimetry Gmbh has now subscribed for and paid all shares.
As previously announced, the Board of Directors of ScandiDos has, with the support of issue authorization from the Annual General Meeting, resolved on the Directed Issue. All newly issued shares have now been subscribed for and paid for by IBA Dosimetry GmbH, which has also been allotted the shares.
Through the Directed Issue, the number of shares and votes in ScandiDos increases by 4,150,000 (from 41,458,870 to 45,608,870). The share capital increases by SEK 207,500 (from SEK 2,072,943.50 to SEK 2,280,443.50).
CONTACT
Gustaf Piehl, CEO, ScandiDos: investor@scandidos.com, +46 18-472 30 20
ScandiDos AB (publ), 556613-0927
Uppsala Science Park, 751 83 Uppsala
ABOUT SCANDIDOS
ScandiDos is an innovative forward-thinking company with groundbreaking software and hardware solutions for patient quality assurance in modern radiation therapy. Our Delta4 Family of products delivers a comprehensive QA solution, making the treatment process safe and efficient. We reinforce the confidence in radiotherapy clinics by providing professionals at the clinics with power and performance through independent QA.
The head office is in Uppsala Science Park, where product development is carried out. Sales are carried out by sales offices in the USA, Malaysia, and France, directly in the Nordic countries and through distributors in over 50 countries.
ScandiDos is listed on NASDAQ First North Stockholm with the ticker code SDOS. Certified adviser is Erik Penser Bank (08-463 83 00, certifiedadviser@penser.se). Additional investor information can be found at Scandidos.com. Product information can be found on Delta4family.com